The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research by Eline A.M. Ruigrok, Wytske M. van Weerden, Julie Nonnekens, Marion de Jong

Get full text

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches by Marjolein Verhoeven, Eline A. M. Ruigrok, Geert J. L. H. van Leenders, Lilian van den Brink, Hayri E. Balcioglu, Wytske M. van Weerden, Simone U. Dalm

Get full text

Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity by Giulia Tamborino, Marijke De Saint-Hubert, Lara Struelens, Dayana C. Seoane, Eline A. M. Ruigrok, An Aerts, Wiggert A. van Cappellen, Marion de Jong, Mark W. Konijnenberg, Julie Nonnekens

Get full text

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment by Eline A. M. Ruigrok, Nicole S. Verkaik, Erik de Blois, Corrina de Ridder, Debra Stuurman, Stefan J. Roobol, Dik C. Van Gent, Marion de Jong, Wytske M. Van Weerden, Julie Nonnekens

Get full text